Skip to content
★ Sign in to follow
Rapport Therapeutics, Inc. logo

Rapport Therapeutics, Inc. Stock: price and insider trades · United States

US·Mcap US$1.6BHealth Care

7 insiders bought €19.8M of shares over the last 90 days, the latest by HEALY JAMES, filed 30 Oct 2026.

Cluster: 7 buyers in 30 days
Insider Decl.
138
Thresholds
n/a
Buy Volume
€31M
35 ops. · all time
Sell Volume
€28M
84 ops. · all time

Who traded when

BuySale
Abraham Ceesay44 sales
Bredt David21 sales
Yeleswaram Krishnaswamy11 sales
Cheryl Gault7 sales
James Healy4 buys
Steven M. Paul3 buys

+7 other insiders

Since the insiders bought

  • Filed 30 Oct 2026 · 18 days ago · €18.0M
    +2.9%
    Entry US$25.13 · Close 12 Nov 2026 US$25.85
  • Filed 23 Oct 2026 · 25 days ago · €88k
    +2.1%
    Entry US$25.33 · Close 12 Nov 2026 US$25.85
  • Filed 22 Oct 2026 · 26 days ago · €89k
    -0.3%
    Entry US$25.93 · Close 12 Nov 2026 US$25.85

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Analyst consensus: bullish or bearish?

Analysts rate Rapport Therapeutics, Inc. Strong Buy (bullish), based on 14 analysts. Average price target: US$64.21.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Financial data

as of FY 2025

FY ended December 2025 · cache

US$27.02
Analyst consensus
14 analysts
Strong buy
US$47.00Target US$64.21(+138%)US$89.00
Income statement
EBITDA-US$124.1M
Net income-US$111.5M0.0% margin
Valuation
PER (forward)-6.5x
P/Book3.3x
Beta1.40
Balance sheet & cash
Market capUS$1.6B
Total debtUS$11.5M
Free Cash Flow-US$88.1M
Debt / Equity2%
Profitability & ownership
ROE-33.3%
ROA-22.0%
% insiders3.2%
% institutions89.5%
Last declaration on 3 November 2026

T+90 is the date 90 days after the filing, the exit horizon used to measure each purchase.

Declarations138 total
  • ◆
    Related company / holdingExecutives
    5M USD27SEC
    238,095 shares@ US$21.000.34% mcap10.8% of flowCommon StockSEC:0001193125-26-445438:0
  • ◆
    Related company / holdingExecutives
    25M USD35SEC
    1,190,476 shares@ US$21.001.69% mcap54.0% of flowCommon StockSEC:0001193125-26-445438:1
  • ▲
    DirectorExecutives
    20M USD57SEC
    952,380 shares@ US$21.001.87% mcap63.9% of flowCommon StockSEC:0001104659-26-120789:0
    Canonical exit: 26 Jan 2027 (T+90)
  • ▲
    DirectorExecutives
    134,295 USD40SEC
    6,395 shares@ US$21.000.013% mcap0.4% of flowCommon StockSEC:0001104659-26-120789:1
    Canonical exit: 26 Jan 2027 (T+90)
  • ▲
    DirectorExecutives
    79,212 USD39SEC
    3,772 shares@ US$21.000.0074% mcap0.3% of flowCommon StockSEC:0001104659-26-120789:2
    Canonical exit: 26 Jan 2027 (T+90)
  • ▲
    DirectorExecutives
    145,593 USD40SEC
    6,933 shares@ US$21.000.014% mcap0.5% of flowCommon StockSEC:0001104659-26-120789:3
    Canonical exit: 26 Jan 2027 (T+90)
  • ▼
    Chief Executive OfficerExecutives
    64,448 USD43SEC
    2,210 shares@ US$29.16180.0046% mcap0.8% of flowCommon StockSEC:0001193125-26-430504:0
  • ▲
    DirectorExecutives
    98,478 USD46SEC
    3,600 shares@ US$27.35490.0070% mcap100.0% of flowCommon StockSEC:0001193125-26-430397:0
    Canonical exit: 21 Jan 2027 (T+90)
  • ▲
    DirectorExecutives
    99,636 USD46SEC
    3,680 shares@ US$27.0750.0071% mcap100.0% of flowCommon StockSEC:0001193125-26-429075:0
    Canonical exit: 20 Jan 2027 (T+90)
  • ▲
    DirectorExecutives
    99,992 USD42SEC
    3,789 shares@ US$26.390.0071% mcap41.9% of flowCommon StockSEC:0001193125-26-429074:0
    Canonical exit: 20 Jan 2027 (T+90)
  • ▲
    DirectorExecutives
    974,278 USD49SEC
    35,714 shares@ US$27.280.069% mcap49.8% of flowCommon StockSEC:0001193125-26-429073:0
    Canonical exit: 20 Jan 2027 (T+90)
  • ▲
    DirectorExecutives
    217,344 USD48SEC
    8,239 shares@ US$26.37990.015% mcap87.3% of flowCommon StockSEC:0001193125-26-429071:0
    Canonical exit: 20 Jan 2027 (T+90)
  • ▲
    DirectorExecutives
    31,547 USD39SEC
    1,172 shares@ US$26.91730.0022% mcap12.7% of flowCommon StockSEC:0001193125-26-429071:1
    Canonical exit: 20 Jan 2027 (T+90)
  • ▲
    Chief Financial OfficerExecutives
    143,550 USD32SEC
    5,500 shares@ US$26.100.010% mcap58.2% of flowCommon StockSEC:0001193125-26-428018:0
    Canonical exit: 19 Jan 2027 (T+90)
  • ▼
    Chief Executive OfficerExecutives
    108,106 USD40SEC
    3,375 shares@ US$32.03140.0070% mcap1.9% of flowCommon StockSEC:0001193125-26-417919:0
  • ▼
    Chief Executive OfficerExecutives
    35,167 USD40SEC
    1,147 shares@ US$30.660.0023% mcap0.6% of flowCommon StockSEC:0001193125-26-417919:1
  • ●
    OfficerExecutives
    1M USD25Source
    39,470 shares@ US$31.150.080% mcap23.7% of flowCommonSEC144:0001958244-26-000649
  • ▼
    Chief Operating OfficerExecutives
    261,813 USD35SEC
    7,925 shares@ US$33.03640.016% mcap38.2% of flowCommon StockSEC:0001193125-26-410734:0
  • ▼
    Chief Operating OfficerExecutives
    70,043 USD30SEC
    2,075 shares@ US$33.75560.0044% mcap10.2% of flowCommon StockSEC:0001193125-26-410734:1
  • ●
    OfficerExecutives
    330,200 USD25Source
    10,000 shares@ US$33.020.021% mcap45.1% of flowCommonSEC144:0001950047-26-009884
  • ▼
    Chief Executive OfficerExecutives
    76,230 USD43SEC
    1,952 shares@ US$39.05230.0057% mcap1.3% of flowCommon StockSEC:0001193125-26-401017:0
  • ▼
    Chief Executive OfficerExecutives
    8,570 USD43SEC
    215 shares@ US$39.86020.0006% mcap0.1% of flowCommon StockSEC:0001193125-26-401017:1
  • ▼
    Chief Executive OfficerExecutives
    1,765 USD43SEC
    43 shares@ US$41.050.0001% mcap0.0% of flowCommon StockSEC:0001193125-26-401017:2
  • ▼
    Chief Executive OfficerExecutives
    325,308 USD46SEC
    7,141 shares@ US$45.5550.022% mcap4.0% of flowCommon StockSEC:0001193125-26-386436:0
  • ▼
    Chief Executive OfficerExecutives
    49,190 USD43SEC
    1,069 shares@ US$46.01470.0034% mcap0.6% of flowCommon StockSEC:0001193125-26-386436:1

25 of 138 declarations

About Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc. (XNAS, Health Care sector, market capitalisation of 1,601,735,680 USD) has just seen a week of purchases: from October 21, 2026 to October 28, 2026, 7 filers bought for EUR 19,776,784. James Healy (Director) bought EUR 17,971,982 on October 28, 2026, after a EUR 7,432,012 purchase on June 10, 2024. Steven M. Paul (Director) bought EUR 867,302 on October 22, 2026. The pack counts 16 cluster-buy filings.

In all, the record of 138 filings, published from June 10, 2024 to November 3, 2026, holds 35 purchases worth EUR 31,124,727 (median EUR 91,615) and 84 sales worth EUR 28,243,958 (median EUR 77,027). The largest sale, EUR 14,576,628 on April 17, 2026, is by Third Rock Ventures V, L.P. (10% Owner). Krishnaswamy Yeleswaram (Chief Development Officer) sold EUR 896,782 on August 25, 2026, and Abraham Ceesay (Chief Executive Officer) EUR 876,942 on September 17, 2025.

Read moreShow less

Abraham Ceesay has 44 filings, all of them sales. Over 12 months: 88 filings, 11 purchases and 64 sales. For 24 purchases tracked at 90 days, the median is -13.9% with 29% positive: stored past results, not a forecast.

Written on 12 November 2026 from the filings and market data available that day. Live figures are in the blocks above.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations

The weekly insider digest, free

One email on Fridays: the insider clusters and single-name signals worth reading. Unsubscribe in one click.